Atazanavir sulfate + cobicistat for the treatment of HIV infection

References

• THE GAP REPORT. UNAIDS, 2014. [cited 2017 May 2]. Available from: http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf.
   Google Scholar
• UN Joint Programme on HIV/AIDS (UNAIDS), Global AIDS Update - 2016, June 2016. [cited 2017 May 2]. Available from: http://www.unaids.org/en/resources/documents/2016/Global-AIDS-update-2016.
   Google Scholar
• INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015;373(9):795–807.
   PubMed Web of Science ®Google Scholar
• TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, Gabillard D, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med 2015;373(9):808–822.
   PubMed Web of Science ®Google Scholar
• Cohen MS, Chen YQ, McCauley M, et al. HPTN052 study team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. [cited 2017 May 2]. Available from: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdfhttp://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
   Google Scholar
• EACS. EACS Guidelines - Version 8.1 - October 2016. [cited 2017 May 2]. Available from: http://eacsociety.org/.
   Google Scholar
• Waters L, Ahmed N, Angus B, et al. BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update). [cited 2017 May 2]. Avaialble from: http://www.bhiva.org/HIV-1-treatment-guidelines.aspx.
   Google Scholar
• Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel. Jama. 2016;316(2):91–210.
   PubMed Web of Science ®Google Scholar
• Arya V, Robertson SM, Struble KA, et al. Scientific considerations for pharmacoenhancers in antiretroviral therapy. J Clin Pharmacol. 2012;52(8):1128–1133.
   PubMed Web of Science ®Google Scholar
• Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the Data Collection on AEs of Anti-HIV Drugs (D:A:D) study. J Infect Dis. 2010;201(3):318–330.
   PubMed Web of Science ®Google Scholar
• Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Int Med. 2010;170:1228–1338.
   PubMed Web of Science ®Google Scholar
• Monforte A, Reiss P, Ryom L, et al. Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. Aids. 2013;27(3):407–415.
   PubMed Web of Science ®Google Scholar
• Molina JM, Andrade-Villaneuva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. 2010;53:323–332.
   PubMed Web of Science ®Google Scholar
• Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154(7):445–456.
   PubMed Web of Science ®Google Scholar
• Lennox JL, Landovitz RJ, Ribaudo HJ, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014;161(7):461–471.
   PubMed Web of Science ®Google Scholar
• Aberg JA, Tebas P, Overton ET, et al. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses. 2012;28:1184–1195.
   PubMed Web of Science ®Google Scholar
• Bertz RJ, Persson A, Chung E, et al. Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve. Pharmacotherapy. 2013;33(3):284–294.
   PubMed Web of Science ®Google Scholar
• Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet. 1998;35(4):275–291.
   PubMed Web of Science ®Google Scholar
• Xu L, Liu H, Hong A, et al. Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350). Bioorg Med Chem Lett. 2014;24(3):995–999.
   PubMed Web of Science ®Google Scholar
• Marzolini C, Gibbons S, Khoo S, et al. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. J Antimicrob Chemother. 2016;71(7):1755–1758.
   PubMed Web of Science ®Google Scholar
• Xu L, Liu H, Murray BP, et al. Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Med Chem Lett. 2010;1(5):209–213.
   PubMed Web of Science ®Google Scholar
• Elion R, Cohen C, Gathe J, et al. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection. Aids. 2011;25(15):1881–1886.
   PubMed Web of Science ®Google Scholar
• Kakuda TN, Opsomer M, Timmers M, et al. Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers. J Clin Pharmacol. 2014;54:949–957.
   PubMed Web of Science ®Google Scholar
• German P, Warren D, West S, et al. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr. 2010;55(3):323–329.
   PubMed Web of Science ®Google Scholar
• Lepist EI, Zhang X, Hao J, et al. Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. Kidney Int. 2014;86(2):350–357.
   PubMed Web of Science ®Google Scholar
• German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr. 2012;61:32–40.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Koenig E, Andrade-Villanueva J, et al. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. J Infect Dis. 2013;208:32–39.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. Aids. 2010;24:1667–1678.
   PubMed Web of Science ®Google Scholar
• Young J, Schäfer J, Fux CA, et al. Swiss HIV Cohort Study. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. Aids. 2012;26(5):567–575.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Viread. [ cited 2017 May 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022577lbl.pdf
   Google Scholar
• Bam RA, Yant SR, Cihlar T. Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity. Antivir Ther. 2014;19(7):687–692.
   PubMed Web of Science ®Google Scholar
• Sax PE, Zolopa A, Brar I, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2014;67(1):52–58.
   PubMedGoogle Scholar
• Mills A, Crofoot G Jr, McDonald C, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2015;69(4):439–445.
   PubMed Web of Science ®Google Scholar
• Sax PE, Wohl D, Yin MT, et al. GS-US-292-0104/0111 study team. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385(9987):2606–2615.
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Warren D, Wei L, et al. Pharmacokinetic boosting of atazanavir with the pharmacoenhancer GS-9350 versus ritonavir. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, USA; Sep 12-15, 2009.
   Google Scholar
• Sevinsky H, Tao X, Wang R, et al. A randomized trial in healthy subjects to assess the bioequivalence of an atazanavir/cobicistat fixed-dose combination tablet versus administration as separate agents. Antivir Ther. 2015;20(5):493–500.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Koenig E, Andrade-Villanueva J, et al. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. J Infect Dis. 2013;208(1):32–39.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Koenig E, Andrade-Villanueva JF, et al. Brief report: cobicistat compared with ritonavir as a pharmacoenhancer for atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate: week 144 results. J Acquir Immune Defic Syndr. 2015;69(3):338–340.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Moyle G, Berenguer J, et al. Atazanavir plus cobicistat: week 48 and week 144 subgroup analyses of a phase 3, randomized, double-blind, active-controlled trial. Curr HIV Res. 2016 Oct 21. Epub ahead of print.
   PubMedGoogle Scholar
• US Food and Drug Administration. New drug application for EVOTAZ®(atazanavir/cobicistat) tablet, 300 mg and 150 mg [updated 2015 Jan 29; cited 2016 Mar 14]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/206353Orig1s000ltr.pdf
   Google Scholar
• Bristol-Myers Squibb Company. Prescribing information for EVOTAZ® (atazanavir and cobicistat) [updated 2015 May; cited 2015 Nov 23]; Available from: http://packageinserts.bms.com/pi/pi_evotaz.pdf
   Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). Evotaz. European Medicines Agency; 2015 May.
   Google Scholar
• McDonald CK, Martorell C, Ramgopal M, et al. Cobicistat-boosted protease inhibitors in HIV-infected patients with mild to moderate renal impairment. HIV Clin Trials. 2014;15(6):269–273.
   PubMed Web of Science ®Google Scholar
• Cure S, Bianic F, Espinas C, et al. Systematic literature review and meta-analysis of renal function in human immunodeficiency virus (HIV)-infected patients treated with atazanavir (ATV)-based regimens. Plos One. 2015;10(5):e0124666.
   Google Scholar
• University of Liverpool. The HIV drug interactions. [cited 2017 May 2]. Available from: http://www.hiv-druginteractions.org/
   Google Scholar
• Carey D, Amin J, Boyd M, et al. Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2010;65(9):1878–1888.
   PubMed Web of Science ®Google Scholar
• Dekker D, Dorresteijn MJ, Pijnenburg M, et al. The bilirubin-increasing drug atazanavir improves endothelial function in patients with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2011;31(2):458–463.
   PubMed Web of Science ®Google Scholar
• Stein JH, Ribaudo HJ, Hodis HN, et al. A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. Aids. 2015;29(14):1775–1783.
   PubMed Web of Science ®Google Scholar
• Chow D, Shikuma C, Ritchings C, et al. Atazanavir and cardiovascular risk among human immunodeficiency virus-infected patients: a systematic review. Infect Dis Ther. 2016;5(4):473–489.
   PubMed Web of Science ®Google Scholar
• Calvez V, Hocqueloux L, Meynard JL, et al. Less-drug regimen including atazanavir in maintenance treatment of HIV infection: how, who, when, why? J Antimicrob Chemother. 2017;72(1):19–28.
   Google Scholar
• Guichet E, Aghokeng A, Serrano L, et al. Short communication: highviral load and multidrug resistance due to late switch to second-line regimens could be a major obstacle to reach the 90-90-90 UNAIDS objectives in Sub-Saharan Africa. AIDS Res Hum Retroviruses. 2016;32(12):1159–1162.
   PubMed Web of Science ®Google Scholar